Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. April 26, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02790 Journal of Clinical Oncology - published online before print April 26, 2023 Flashback Foreword: Bevacizumab + Carboplatin/Paclitaxel in NSCLC Thomas E. Stinchcombe , MD1,2xThomas E. StinchcombeSearch for articles by this author Show More 1Associate Editor, Journal of Clinical Oncology, Alexandria, VA2Duke Cancer Institute, Durham, NC https://doi.org/10.1200/JCO.22.02790 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYThis randomized phase II trial1 compared carboplatin and paclitaxel alone (the control arm) with carboplatin and paclitaxel with bevacizumab at two doses in patients with non–small-cell lung cancer (NSCLC). Bevacizumab 15 mg/kg once every 3 weeks was the dose selected for future clinical trials, and an excessive rate of toxicity was observed in the subset of patients with squamous histology, leading to the exclusion of patients with NSCLC with squamous histology from future trials of bevacizumab in NSCLC.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non–Small-Cell Lung CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Thomas E. StinchcombeThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: EMD Serono, Janssen Oncology, Turning Point Therapeutics, Sanofi/Aventis, GlaxoSmithKline, Genentech/Roche, Daiichi Sankyo/Astra Zeneca, Takeda, Eisai/H3 Biomedicine, G1 Therapeutics, Spectrum PharmaceuticalsResearch Funding: AstraZeneca (Inst), Takeda (Inst), Regeneron (Inst), Seattle Genetics (Inst), Mirati Therapeutics (Inst), Genentech/Roche (Inst)No other potential conflicts of interest were reported. Companion Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer